OrbiMed’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.3M | Hold |
61,600
| – | – | 0.25% | 80 |
|
|
2026
Q1 | $11.3M | Buy |
+61,600
| New | +$11.4M | 0.22% | 79 |
|
|
2025
Q1 | – | Sell |
-509,100
| Closed | -$77.9M | – | 111 |
|
|
2024
Q4 | $77.9M | Sell |
509,100
-303,900
| -37% | -$51.3M | 1.6% | 20 |
|
|
2024
Q3 | $158M | Sell |
813,000
-87,900
| -10% | -$18.4M | 2.86% | 7 |
|
|
2024
Q2 | $209M | Hold |
900,900
| – | – | 4.12% | 6 |
|
|
2024
Q1 | $194M | Buy |
900,900
+73,300
| +9% | +$17.2M | 3.56% | 6 |
|
|
2023
Q4 | $214M | Buy |
827,600
+270,800
| +49% | +$66.5M | 4.28% | 2 |
|
|
2023
Q3 | $143M | Hold |
556,800
| – | – | 3.04% | 5 |
|
|
2023
Q2 | $159M | Buy |
556,800
+51,800
| +10% | +$15.4M | 2.87% | 6 |
|
|
2023
Q1 | $140M | Buy |
505,000
+246,800
| +96% | +$68.3M | 2.76% | 9 |
|
|
2022
Q4 | $71.5M | Buy |
258,200
+33,600
| +15% | +$9.49M | 1.37% | 25 |
|
|
2022
Q3 | $60M | Buy |
224,600
+113,000
| +101% | +$24M | 1.11% | 33 |
|
|
2022
Q2 | $22.8M | Sell |
111,600
-6,300
| -5% | -$1.29M | 0.41% | 58 |
|
|
2022
Q1 | $24.8M | Sell |
117,900
-112,300
| -49% | -$24.4M | 0.4% | 61 |
|
|
2021
Q4 | $55.2M | Sell |
230,200
-4,000
| -2% | -$1.03M | 0.71% | 47 |
|
|
2021
Q3 | $66.3M | Buy |
234,200
+166,800
| +247% | +$54.7M | 0.73% | 44 |
|
|
2021
Q2 | $23.3M | Sell |
67,400
-14,600
| -18% | -$4.42M | 0.24% | 90 |
|
|
2021
Q1 | $22.9M | Sell |
82,000
-447,400
| -85% | -$121M | 0.21% | 92 |
|
|
2020
Q4 | $130M | Sell |
529,400
-186,500
| -26% | -$48.1M | 1.13% | 23 |
|
|
2020
Q3 | $203M | Hold |
715,900
| – | – | 2.55% | 11 |
|
|
2020
Q2 | $192M | Buy |
715,900
+235,500
| +49% | +$70.8M | 2.7% | 8 |
|
|
2020
Q1 | $152M | Buy |
480,400
+415,900
| +645% | +$126M | 2.55% | 11 |
|
|
2019
Q4 | $19.1M | Buy |
64,500
+28,300
| +78% | +$7.85M | 0.27% | 68 |
|
|
2019
Q3 | $8.43M | Sell |
36,200
-51,500
| -59% | -$12M | 0.16% | 82 |
|
|
2019
Q2 | $20.5M | Hold |
87,700
| – | – | 0.32% | 70 |
|
|
2019
Q1 | $20.7M | Sell |
87,700
-747,549
| -90% | -$235M | 0.32% | 72 |
|
|
2018
Q4 | $251M | Sell |
835,249
-75,051
| -8% | -$24M | 4.65% | 3 |
|
|
2018
Q3 | $322M | Sell |
910,300
-257,600
| -22% | -$88.7M | 3.87% | 3 |
|
|
2018
Q2 | $339M | Buy |
1,167,900
+127,500
| +12% | +$35.8M | 4.04% | 2 |
|
|
2018
Q1 | $285M | Sell |
1,040,400
-190,300
| -15% | -$59.1M | 3.53% | 5 |
|
|
2017
Q4 | $392M | Sell |
1,230,700
-399,300
| -24% | -$128M | 4.96% | 1 |
|
|
2017
Q3 | $510M | Hold |
1,630,000
| – | – | 4.88% | 2 |
|
|
2017
Q2 | $442M | Buy |
1,630,000
+193,100
| +13% | +$51.1M | 4.64% | 3 |
|
|
2017
Q1 | $393M | Buy |
1,436,900
+155,700
| +12% | +$44M | 4.45% | 2 |
|
|
2016
Q4 | $363M | Sell |
1,281,200
-52,700
| -4% | -$15.6M | 4.63% | 2 |
|
|
2016
Q3 | $418M | Sell |
1,333,900
-166,500
| -11% | -$49.3M | 4.76% | 1 |
|
|
2016
Q2 | $363M | Sell |
1,500,400
-25,900
| -2% | -$6.83M | 3.79% | 5 |
|
|
2016
Q1 | $397M | Buy |
1,526,300
+83,800
| +6% | +$22.1M | 4.18% | 7 |
|
|
2015
Q4 | $442M | Buy |
1,442,500
+135,100
| +10% | +$38.8M | 4% | 5 |
|
|
2015
Q3 | $382M | Buy |
1,307,400
+28,500
| +2% | +$9.41M | 3.85% | 7 |
|
|
2015
Q2 | $517M | Buy |
1,278,900
+72,100
| +6% | +$28.9M | 4.32% | 1 |
|
|
2015
Q1 | $510M | Sell |
1,206,800
-287,900
| -19% | -$113M | 4.35% | 2 |
|
|
2014
Q4 | $507M | Buy |
1,494,700
+304,600
| +26% | +$98.5M | 4.85% | 1 |
|
|
2014
Q3 | $394M | Buy |
1,190,100
+105,900
| +10% | +$34.9M | 4.11% | 2 |
|
|
2014
Q2 | $342M | Buy |
1,084,200
+23,500
| +2% | +$7.07M | 4.01% | 3 |
|
|
2014
Q1 | $324M | Sell |
1,060,700
-34,400
| -3% | -$10.9M | 3.99% | 3 |
|
|
2013
Q4 | $306M | Buy |
1,095,100
+68,700
| +7% | +$17.8M | 4.5% | 2 |
|
|
2013
Q3 | $247M | Buy |
1,026,400
+600
| +0.1% | +$134K | 4.41% | 4 |
|
|
2013
Q2 | $221M | Buy |
+1,025,800
| New | +$219M | 4.68% | 3 |
|
Other funds holding BIIB
OrbiMed's BIIB Position: Q2 2026 in Review
OrbiMed held its Biogen (BIIB) position steady in Q2 2026 at 61,600 shares worth $13.3M. The position accounts for 0.25% of the portfolio, ranked #80.
OrbiMed first reported a position in BIIB in Q2 2013 and has held it in 49 quarters since. The position peaked at $517M in Q2 2015. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- OrbiMed held 61,600 shares of Biogen worth $13.3M as of Q2 2026.
- OrbiMed left its Biogen share count unchanged in Q2 2026.
- Biogen made up 0.25% of OrbiMed's portfolio in Q2 2026, its #80 holding.
- OrbiMed first reported a position in Biogen in Q2 2013 and has held it in 49 quarters since.
- OrbiMed's Biogen position peaked at $517M in Q2 2015.
- 1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.